Prostate Cancer

Aglatimagene besadenovec plus ERBT displayed an accumulating benefit in high-risk prostate cancer after extended follow-up.

The top 5 OncLive TV videos of the week cover insights in breast cancer, ovarian cancer, prostate cancer, acute myeloid leukemia, and mantle cell lymphoma.

Long-term follow-up data showed ePLND significantly reduces the risk of metastasis in ISUP GG 3-5 prostate cancer with radical prostatectomy.

TALAPRO-3 showed talazoparib plus enzalutamide cut progression or death risk by 52% in HRR-altered mCSPC vs enzalutamide alone.

PSMAddition subgroup data show lutetium PSMA-617 triplet yields consistent rPFS, PSA, and mCRPC benefits regardless of disease volume or mHSPC status.

Perioperative apalutamide plus ADT improved metastasis-free survival and pathologic responses in high-risk localized prostate cancer.

Nicholas Zorko, MD, PhD, discusses B7-H3 targeting in lung, GU, and gynecologic malignancies.

OncLive spoke with experts in the field of GU oncology to gain their insights on the most notable presentations from the 2026 AUA Annual Meeting.

The top 5 OncLive TV videos of the week cover insights in breast cancer, ovarian cancer, prostate cancer, acute myeloid leukemia, and mantle cell lymphoma.

Enzalutamide plus radium-223 demonstrated no early survival advantage but an 80% death risk reduction for long-term survivors in mCRPC at over 60 months.

Rucaparib showed a manageable and consistent safety profile in patients with BRCA-mutated prostate cancer.

No new safety signals were identified, and imAEs were predominantly low-grade and consistent with the known durvalumab safety profile.

Adding lutetium Lu 177 vipivotide tetraxetan to ADT and ARPI deepened PSA responses and reduced the risk of PSA progression by 58% in patients with mHSPC.

Talazoparib plus enzalutamide data show rPFS correlates moderate-to-strongly with OS in first-line mCRPC across biomarker-defined subgroups.

Enzalutamide plus leuprolide produced a median treatment suspension of 17 months vs 11.5 months with leuprolide alone in biochemically recurrent prostate cancer.

Darolutamide plus ADT demonstrated a 50% reduction in the risk of death in metastatic hormone-sensitive prostate cancer.

Ahead of the 2026 AUA Annual Meeting, GU cancer experts highlighted the abstracts that they are anticipating the most.

Sagar A. Patel, MD, discusses the REVELUTION-2 trial evaluating cardiovascular safety with hormone therapy in prostate cancer.

The AUA and SUO released the 2026 amendment to the Advanced Prostate Cancer Guideline.

[177Lu]Lu-D-Dan-Phe-PSMA showed early signals of safety and activity in mCRPC.

During a recent OncLive Peer Exchange, prostate cancer experts discussed the evolving role of treatment intensification in mCSPC.

The regimen produced a 2-year freedom from biochemical recurrence rate of 90.3% in grade group 5 prostate cancer.

The FDA cleared vepdegestrant in ER+ breast cancer with ESR1 mutations, ODAC voted on key questions in breast and prostate cancer, and more.

Did you catch all of this week's top oncology news? Test your knowledge with OncLive's Weekly News Quiz.

The FDA ODAC voted for the use of capivasertib plus abiraterone in PTEN-deficient mHSPC.